Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

24.95USD
23 Feb 2018
Change (% chg)

$-0.45 (-1.77%)
Prev Close
$25.40
Open
$25.65
Day's High
$26.80
Day's Low
$24.70
Volume
782,116
Avg. Vol
393,880
52-wk High
$27.50
52-wk Low
$3.65

Latest Key Developments (Source: Significant Developments)

Kite, Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For Treatment Of Cancer
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER.SANGAMO THERAPEUTICS - KITE TO RECEIVE EXCLUSIVE LICENSE TO LEVERAGE SANGAMO'S GENE EDITING TECHNOLOGY IN ALLOGENEIC AND AUTOLOGOUS CELL THERAPY PROGRAMS IN ONCOLOGY.SANGAMO THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION.SANGAMO THERAPEUTICS INC - UNDER TERMS, SANGAMO IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS.SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR AGREED UPON EXPENSES INCURRED BY SANGAMO.SANGAMO THERAPEUTICS INC - CO WOULD ALSO RECEIVE TIERED ROYALTIES ON SALES OF POTENTIAL FUTURE PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Sangamo Therapeutics Q4 Loss Per Share $0.15
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $13.1 MILLION VERSUS $8.9 MILLION.Q4 LOSS PER SHARE $0.15.Q4 EARNINGS PER SHARE VIEW $-0.18, REVENUE VIEW $11.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER.SANGAMO THERAPEUTICS INC - SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION AND IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS.SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF PRODUCTS UNDER COLLABORATION.  Full Article

Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant
Wednesday, 7 Feb 2018 07:30am EST 

Feb 7 (Reuters) - Sangamo Therapeutics Inc ::CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV.NO SB-728-T PRODUCT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED IN SANGAMO'S SB-728-T CLINICAL TRIALS.CO WILL BE CONTRIBUTING MATERIALS, EQUIPMENT, AND MANUFACTURING EXPERTISE FOR STUDY, WHICH IS EXPECTED TO BEGIN IN 2018.  Full Article

Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als
Wednesday, 3 Jan 2018 07:31am EST 

Jan 3 (Reuters) - Pfizer Inc ::SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER.SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​.SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES.SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS.  Full Article

Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
Thursday, 7 Dec 2017 04:22pm EST 

Dec 7 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES EUROPEAN MEDICINES AGENCY RECOMMENDATION OF ORPHAN MEDICINAL PRODUCT DESIGNATION FOR INVESTIGATIONAL GENOME EDITING TREATMENTS FOR MPS I AND MPS II.SANGAMO THERAPEUTICS - PHASE 1/2 CLINICAL TRIALS FOR PROGRAMS, EVALUATING SB-318 & SB-913 IN ADULTS WITH MPS I AND MPS II, ARE ENROLLING SUBJECTS.  Full Article

Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​
Wednesday, 15 Nov 2017 01:10am EST 

Nov 15 (Reuters) - Sangamo Therapeutics Inc -:Sangamo announces treatment of first patient in landmark phase 1/2 clinical trial evaluating in vivo genome editing for MPS II.‍A patient has received a therapy intended to precisely edit DNA of cells directly inside body​.  Full Article

Sangamo Therapeutics posts Q3 loss per share $0.15
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports third quarter 2017 financial results.Q3 revenue $11.8 million versus I/B/E/S view $10.4 million.Q3 loss per share $0.15.Sees FY 2017 revenue $30 million to $40 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sangamo Therapeutics Inc - ‍company expects that revenues will be in range of $30 million to $40 million in 2017​.FY2017 revenue view $33.2 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400
Monday, 2 Oct 2017 07:30am EDT 

Oct 2 (Reuters) - Bioverativ Inc :Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia.Sangamo Therapeutics Inc - ‍expects to open several clinical sites across United States and begin enrolling patients in first half of 2018​.Sangamo Therapeutics - based on deal terms, Sangamo responsible for conducting ST-400 phase 1/2 clinical trial.Sangamo Therapeutics - based on deal terms, Bioverativ responsible for subsequent worldwide clinical development, manufacturing, commercialization.  Full Article

Pfizer and Sangamo updates on early stage trial on its blood disorder therapy
Friday, 25 Aug 2017 08:00am EDT 

Aug 25 (Reuters) - Pfizer Inc ::Sangamo and Pfizer announce first patient receives treatment in Phase 1/2 clinical trial evaluating SB-525 investigational gene therapy for Hemophilia A.  Full Article

Photo

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.